Goodwin Represents Underwriters on ImmunityBio's $100.0 Million Public Offering
December 13, 2024
December 13, 2024
BOSTON, Massachusetts, Dec. 13 -- Goodwin, a law firm, issued the following news release:
The Capital Markets team advised the joint lead book-running managers and underwriting syndicate in the completion of ImmunityBio's (Nasdaq: IBRX) underwritten public offering of 33,333,334 shares of its common stock at a public offering price of $3.00 per share for gross proceeds of $100.0 million.
ImmunityBio is a vertically-integrated commercial stage biotechnology company devel . . .
The Capital Markets team advised the joint lead book-running managers and underwriting syndicate in the completion of ImmunityBio's (Nasdaq: IBRX) underwritten public offering of 33,333,334 shares of its common stock at a public offering price of $3.00 per share for gross proceeds of $100.0 million.
ImmunityBio is a vertically-integrated commercial stage biotechnology company devel . . .